Cargando…

Emerging therapies for the treatment of hepatitis C

Opportunities to treat infection with hepatitis C virus (HCV) are evolving rapidly. From the introduction of interferon-α monotherapy in 1992 to the approval of telaprevir- and boceprevir-based triple therapies with pegylated interferon-α and ribavirin in 2011, the chances of curing patients infecte...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lange, Christian M, Jacobson, Ira M, Rice, Charles M, Zeuzem, Stefan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Blackwell 2014
Materias:	Reviews
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3936496/ https://www.ncbi.nlm.nih.gov/pubmed/24106239 http://dx.doi.org/10.1002/emmm.201303131

Ejemplares similares

Concise review: Interferon-free treatment of hepatitis C virus-associated cirrhosis and liver graft infection
por: Weiler, Nina, et al.
Publicado: (2016)

Ribavirin revisited in the era of direct‐acting antiviral therapy for hepatitis C virus infection
por: Feld, Jordan J., et al.
Publicado: (2016)

Predictive Value of Interferon-Lambda Gene Polymorphisms for Treatment Response in Chronic Hepatitis C
por: Susser, Simone, et al.
Publicado: (2014)

Ongoing liver inflammation in patients with chronic hepatitis C and sustained virological response
por: Welsch, Christoph, et al.
Publicado: (2017)

Superiority of Interferon-Free Regimens for Chronic Hepatitis C: The Effect on Health-Related Quality of Life and Work Productivity
por: Younossi, Zobair M., et al.
Publicado: (2017)

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices
por: Afdhal, N H, et al.
Publicado: (2013)

Emerging Therapies for Hepatitis C
por: Kim, Do Young, et al.
Publicado: (2014)

Glycogen Synthase Kinase 3β Enhances Hepatitis C Virus Replication by Supporting miR-122
por: Saleh, Maged, et al.
Publicado: (2018)

Expert opinion on the treatment of patients with chronic hepatitis C
por: Zeuzem, S, et al.
Publicado: (2009)

Hepatitis C Viral Evolution in Genotype 1 Treatment-Naïve and Treatment-Experienced Patients Receiving Telaprevir-Based Therapy in Clinical Trials
por: Kieffer, Tara L., et al.
Publicado: (2012)

Persistence of Hepatitis C Virus during and after Otherwise Clinically Successful Treatment of Chronic Hepatitis C with Standard Pegylated Interferon α-2b and Ribavirin Therapy
por: Chen, Annie Y., et al.
Publicado: (2013)

Hepatitis C Virus: A Critical Appraisal of New Approaches to Therapy
por: Nelson, David R., et al.
Publicado: (2012)

Towards a small animal model for hepatitis C
por: Ploss, Alexander, et al.
Publicado: (2009)

Translation of IRF-1 Restricts Hepatic Interleukin-7 Production to Types I and II Interferons: Implications for Hepatic Immunity
por: Rueschenbaum, Sabrina, et al.
Publicado: (2021)

Behandlung von Hepatitis-C-Infektionen im Zeitalter direkt wirkender antiviraler Medikamente (DAAs)
por: Peiffer, Kai-Henrik, et al.
Publicado: (2022)

Fatigue during treatment for hepatitis C virus: results of self-reported fatigue severity in two Phase IIb studies of simeprevir treatment in patients with hepatitis C virus genotype 1 infection
por: Scott, Jane, et al.
Publicado: (2014)

Consideration of Viral Resistance for Optimization of Direct Antiviral Therapy of Hepatitis C Virus Genotype 1-Infected Patients
por: Dietz, Julia, et al.
Publicado: (2015)

Hypopituitarism in Wilson’s disease resolved after copper-chelating therapy
por: Dauth, Nina, et al.
Publicado: (2021)

Diagnosis and Management of Hepatitis Delta Virus Infection
por: Pan, Calvin, et al.
Publicado: (2023)

Absence of HBV Reactivation in Patients With Resolved HBV Infection Following DAA Therapy for Hepatitis C: A 1-Year Follow-up Study
por: Mücke, Marcus M, et al.
Publicado: (2018)

Managing pediatric hepatitis C: current and emerging treatment options
por: Karnsakul, Wikrom, et al.
Publicado: (2009)

Macrophage-Derived Extracellular Vesicles Induce Long-Lasting Immunity Against Hepatitis C Virus Which Is Blunted by Polyunsaturated Fatty Acids
por: Cai, Chengcong, et al.
Publicado: (2018)

Primary Biliary Cholangitis (PBC)-Autoimmune Hepatitis (AIH) Variant Syndrome: Clinical Features, Response to Therapy and Long-Term Outcome
por: Graf, Markus, et al.
Publicado: (2023)

Baseline MELD Score Predicts Hepatic Decompensation during Antiviral Therapy in Patients with Chronic Hepatitis C and Advanced Cirrhosis
por: Dultz, Georg, et al.
Publicado: (2013)

Glecaprevir/pibrentasvir for the treatment of chronic hepatitis C: design, development, and place in therapy
por: Cotter, Thomas G, et al.
Publicado: (2019)

Natural HCV variants with increased replicative fitness due to NS3 helicase mutations in the C-terminal helix α(18)
por: Stross, Claudia, et al.
Publicado: (2016)

Vitamin D deficiency is associated with hepatic decompensation and inflammation in patients with liver cirrhosis: A prospective cohort study
por: Kubesch, Alica, et al.
Publicado: (2018)

Cyclophilin Inhibitors: An Emerging Class of Therapeutics for the Treatment of Chronic Hepatitis C Infection
por: Hopkins, Sam, et al.
Publicado: (2012)

A Genetic Validation Study Reveals a Role of Vitamin D Metabolism in the Response to Interferon-Alfa-Based Therapy of Chronic Hepatitis C
por: Lange, Christian M., et al.
Publicado: (2012)

Hepatitis C Virus in North Africa: An Emerging Threat
por: Daw, Mohamed A., et al.
Publicado: (2016)

Emerging medical therapies for severe alcoholic hepatitis
por: Tornai, David, et al.
Publicado: (2020)

Utilization and effectiveness of elbasvir/grazoprevir and adoption of resistance-associated substitutions testing in real-world treatment of hepatitis C virus genotype 1A infection: results from the German Hepatitis C-Registry
por: Hinrichsen, Holger, et al.
Publicado: (2020)

Emerging resistance to directly-acting antiviral therapy in treatment of chronic Hepatitis C infection—A brief review of literature
por: Bhatia, Mohit, et al.
Publicado: (2020)

Benefit–risk assessment of new and emerging treatments for hepatitis C: focus on simeprevir and sofosbuvir
por: Gaetano, John N
Publicado: (2014)

Hepatic sarcoidosis: Clinical characteristics and outcome
por: Graf, Christiana, et al.
Publicado: (2021)

Elbasvir/Grazoprevir in People With Hepatitis C Genotype 1 Infection and Child-Pugh Class B Cirrhosis: The C-SALT Study
por: Jacobson, Ira M., et al.
Publicado: (2019)

Interferon-free combination therapies for the treatment of hepatitis C: current insights
por: Holmes, Jacinta A, et al.
Publicado: (2015)

Alox12/15 Deficiency Exacerbates, While Lipoxin A(4) Ameliorates Hepatic Inflammation in Murine Alcoholic Hepatitis
por: Queck, Alexander, et al.
Publicado: (2020)

Hepatitis C Virus: A Review of Treatment Guidelines, Cost-effectiveness, and Access to Therapy
por: Lynch, Shaina M., et al.
Publicado: (2016)

Treatment of Hepatitis C in Patients Undergoing Immunosuppressive Drug Therapy
por: Ooka, Kohtaro, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_na9hn331kj6f3khbf6o3lil40q